Investigating a new protein's role in fighting aggressive breast cancer
Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer
This study is looking at a protein called UBR7 to see how it might help fight triple negative breast cancer, which is a tough type of cancer to treat, and aims to find new ways to target it for better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10817146 on NIH RePORTER |
What this research studies
This research focuses on understanding how a protein called UBR7 may help suppress triple negative breast cancer (TNBC), which is known for being particularly aggressive and lacking targeted treatments. The study aims to explore the epigenomic changes in breast cancer cells, specifically how UBR7 modifies histones, which are proteins that help package DNA. By examining these modifications, researchers hope to identify new therapeutic strategies that could target specific molecular features of TNBC, potentially leading to more effective treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer.
Not a fit: Patients with non-breast cancers or those with breast cancer subtypes other than triple negative may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with triple negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting epigenetic modifications in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Rai, Kunal — University of Tx Md Anderson Can Ctr
- Study coordinator: Rai, Kunal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.